Quick Takeaways Why It Matters? Loyal’s raise reinforces longevity as a serious, institution-backed frontier in veterinary medicine, moving it from niche concept to an emerging preventive care category. If LOY-002 secures conditional and then full approval, it could...
Quick Takeaways: Why It Matters? With both TAS and RXE accepted, Loyal moves significantly closer to commercializing the first true longevity drug in veterinary medicine, turning canine lifespan extension into a near-term, rather than speculative, market. If LOY-002 reache...
